ProChon Biotech Ltd. says it will likely release the results from expanded clinical trials of its BioCart knee cartilage repair treatment by June.
The Woburn, Mass.-based company, which recently raised about $4 million in a convertible bridge loan to finance the trials, said it’s about halfway through the patient enrollment process in the Phase II study and expects results to be released in three months.
ProChon is developing a system to repair damaged cartilage called the BioCart system, which uses proprietary fibroblast growth factor technology to help regenerate damaged cartilage in the knee.
In a press release, the firm said it would be presenting educational information on the BioCart system to attendees of the Annual Meeting of the American Academy of Orthopaedic Surgeons March 10-12.
